Technology

Mixed Reviews for AriBio’s Phase 3 Alzheimer’s Drug Trial... Possibility of Additional Clinical Trials Raised

KIM SUNG-JIN
2026-11-19 07:47:03
[Edaily KIM SUNG-JIN Reporter Kim Saemi] Although AriBio’s oral Alzheimer’s disease treatment candidate “AR1001” met its pre-specified primary efficacy endpoint in a global Phase 3 clinical trial, industry observers predict that the company will face significant hurdles in securing approval from the U.S. Food and Drug Administration (FDA). This is because, while the drug demonstrated efficacy in the monotherapy group, it failed to achieve statistical significance in the overall patient population. Since meeting clinical trial criteria and securing the basis for FDA approval are two separate matters, attention is now focused on whether additional data analysis will be required in the future.
Sharon Sha, Director of the Memory Disorders Division at Stanford University in the U.S., presenting the results of the Phase 3 clinical trial for “AR1001” at the Clinical Trials in Alzheimer’s Disease (CTAD) conference held in Boston, U.S., on the 16th (local time). (Photo courtesy of AriBio.)

Monotherapy Group Met Targets… No Statistical Significance Achieved in Overall Patient Population
According to the pharmaceutical and biotech industry on the 17th, AriBio unveiled the key results of the global Phase 3 clinical trial “POLARIS-AD” for AR1001 at the International Conference on Alzheimer’s Disease Clinical Trials (CTAD 2026) held in Boston, U.S. This trial was conducted at approximately 230 medical institutions across 13 countries, including South Korea and the U.S., involving 1,535 patients with early-stage Alzheimer’s disease. Participants took either 30 mg of AR1001 or a placebo once daily for 52 weeks.

A key feature of this trial was that it was conducted with two groups: a monotherapy group and an overall patient group. The monotherapy group, as the name implies, consisted of patients (604) who received only AR1001, AriBio’s Alzheimer’s disease drug candidate, while the overall patient population refers to all 1,535 clinical trial participants, including those in the monotherapy group. The two groups were designated prior to the start of the trial and were designed such that achieving statistical significance in either group would be considered fulfillment of the primary efficacy endpoint.

The overall significance level of 0.05 was allocated as 0.03 for the monotherapy group and 0.02 for the overall patient population. An overall significance level of 0.05 is a statistical criterion that limits the probability of falsely concluding that a treatment is effective to a maximum of 5% in a clinical trial.

Aribio’s AR1001 succeeded in achieving statistical significance in the monotherapy group. Specifically, the CDR-SB score in the AR1001 treatment group was 0.96, which was 0.44 points lower than the 1.40 recorded in the placebo group. The CDR-SB is an indicator that assesses the severity of dementia by combining six domains, including memory, judgment, and the ability to perform activities of daily living; a higher score indicates more severe symptoms. The p-value indicating statistical significance was 0.0266, meeting the pre-specified threshold of 0.03.

In contrast, different results were observed in the overall patient population. The difference in CDR-SB scores between the AR1001 treatment group and the placebo group was only 0.11 points, and the p-value of 0.4015 failed to reach statistical significance. The rate of disease progression delay in the overall patient population was approximately 7%, lower than the 31% observed in the monotherapy group.

Mixed Results for Secondary Endpoints… “Potential for Additional Clinical Trials”
Consistent efficacy was not observed in the key secondary endpoints either. On the 13-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-Cog13), the AR1001 treatment group in the monotherapy arm showed a 1.16-point advantage over the placebo group; however, with a p-value of 0.0798, this result did not reach statistical significance. In another cognitive function test, the Mini-Mental State Examination (MMSE), a 0.7-point difference was observed compared to the placebo, and the p-value of 0.0232 indicated statistical significance. In the ADAS-Cog13, a lower score indicates better cognitive function, while in the MMSE, a higher score indicates better cognitive function.

Biomarker analysis yielded some positive results. cGMP levels in cerebrospinal fluid—which are related to AR1001’s mechanism of action—increased significantly compared to the placebo in both the overall patient group and the monotherapy group. In contrast, p-tau217, which is associated with the pathology of Alzheimer’s disease, showed a significant difference only in the monotherapy group, while no significant difference was observed in the amyloid-beta ratio (Aβ42/40). Biomarkers are indicators used to confirm whether pathological changes associated with Alzheimer’s disease or drug effects are occurring in the brain.

Experts suggest that since statistical significance was achieved only in the monotherapy group, obtaining FDA approval may not be easy. A biotech industry expert and former FDA reviewer advised, “If efficacy is observed with monotherapy but not when added to existing treatments, the implications must be carefully examined.” He continued, “We must first identify the cause of these conflicting results,” adding, “We need to examine whether it was due to sample size or statistical issues, or if there was a bias related to patient characteristics.”

The difficulty in establishing objective metrics due to the nature of Alzheimer’s disease is also seen as a stumbling block. An official from a biotech venture capital (VC) firm commented, “While they claim to have met the primary endpoint, the CDR-SB, this metric does not measure objective numerical values like a biomarker but rather scores the patient’s condition,” adding, “There is room for subjective judgment to influence the evaluation process.”

Consequently, some analysts suggest that the FDA may require additional clinical trials. An expert from the Korea Drug Development Foundation (KDDF) expressed the opinion, “Statistical significance was not achieved in the overall patient population, but efficacy appears to be evident in the monotherapy group; in such cases, I believe there is a possibility that additional clinical trials will be required.” He added, “Unlike existing antibody therapies, the fact that this treatment can be administered orally makes a significant difference in terms of convenience. If it succeeds properly, it could bring about significant changes in the market,” he said, adding, “However, whether the FDA will approve it based on these results is a separate issue, and we must also consider what position this new treatment can occupy within a competitive landscape dominated by major pharmaceutical companies.”

However, AriBio maintains that the trial itself was a success, given that positive results were observed in the monotherapy group. The clinical trial design, which received approval from U.S. and European regulatory authorities, was structured to evaluate both the overall patient population and the monotherapy group separately; if either group met the pre-specified statistical significance criteria, the primary efficacy endpoint was deemed achieved. An AriBio official said, “We developed this protocol in consultation with U.S. and European regulatory agencies when applying for approval of the clinical trial plan,” adding, “We agreed that the trial would be considered a success if significant results were obtained in even one of the two groups—the monotherapy group or the overall patient group.”

Another biotech industry expert, a former FDA reviewer, also expressed a cautious stance. He remarked, “While the primary endpoint (CDR-SB) was met, and since the primary endpoint was likely determined in consultation with the FDA, these statistical analysis criteria were likely possible because the FDA approved them,” adding, “First and foremost, we can attach significance to the fact that this is an oral Alzheimer’s disease treatment, and I do not necessarily believe the FDA will require additional clinical trials.”
Market Reaction Is Icy… A Turning Point for Fusing Pharmaceutical’s Option Exercise
The market’s reaction to AriBio’s latest clinical results has been decidedly cold. On the KOSDAQ market that day, AriBio Lab, a listed subsidiary of AriBio, hit the daily price limit down, while AriBio Holdings’ stock price fell 29.86%, coming close to the limit down. Analysts attribute this sharp drop in stock prices to the fact that, despite meeting the pre-specified endpoints of the Phase 3 clinical trial, the treatment’s efficacy was not statistically proven across the entire patient population. It is also interpreted that the efficacy observed only in the monotherapy group is unlikely to lead to FDA approval.

Under these circumstances, whether Fuxing Pharmaceutical exercises its option has emerged as a key point of interest. Fuxing Pharmaceutical, a major pharmaceutical company listed on the Shanghai and Hong Kong stock exchanges, signed an exclusive option agreement with AriBio in May regarding the global commercialization of AR1001. The agreement allows Fuxing Pharmaceutical to acquire rights in major markets such as the U.S., Europe, and Japan, in addition to the rights it already holds in China and 10 Southeast Asian countries. Under this agreement, AriBio received the full option fee of $60 million (approximately 90 billion won).

The key feature of the agreement is that it allows Fuxing Pharmaceutical to decide whether to actually secure additional distribution rights after reviewing the Phase 3 clinical trial results. According to Fuxing Pharmaceutical’s interim report for this year, the company has 90 days from the date it receives the full topline data from the Phase 3 clinical trial of AR1001 to decide whether to exercise the option. If the option is exercised, Fuxing Pharmaceutical will pay AriBio an upfront payment of $80 million (approximately 107 billion won) and regulatory milestones totaling up to $100 million (approximately 133.9 billion won).

In a separate disclosure regarding the Phase 3 clinical trial results for AR1001 released today, Fosun Pharma stated that it has not yet exercised the exclusive option to secure additional licensing rights. Fosun Pharma explained that while the primary efficacy endpoint was met in the monotherapy group, statistical significance was not achieved in the overall patient population, and that it plans to decide whether to exercise the option after further analyzing and evaluating the study data, including the Phase 3 topline results.

Industry observers speculate that if Fuxing Pharmaceutical views these Phase 3 clinical trial results positively, it will make a swift decision on whether to exercise the option. They note that Fuxing Pharmaceutical’s decision on whether to exercise the option could serve as a barometer for the likelihood of FDA approval.

An official from AriBio stated, “Representatives from Fuxing Pharmaceutical also attended the conference in the U.S.,” adding, “We’ve heard that the atmosphere was positive.”

Economy

Corporation

IT·Science

Economy

Will Stock Prices Rise If Acquisition Thresholds Are Lowered?…The Dilemma of Hostile M&A

As the government considers hostile mergers and acquisitions (M&A) as a means to enhance corporate value, calls are growing for the establishment of institutional safeguards before revitalizing the ac…
2026-11-19 06:50:04

Corporation

SamyangFoods’ Holding Company Establishes Wind Power Subsidiary in Pyeongchang… Pursuing New Mid- to Long-Term Business Ventures

Samyang Round Square, the holding company of SamyangFoods(003230), has established a wind power generation subsidiary in Pyeongchang, Gangwon Province. This move is intended to pursue a “repowering” p…
2026-11-18 18:14:36

IT·Science

Graphy Inc. Sees 52% Increase in SMA Orders… Demand for Follow-up Correction Devices Also Rises

#Orders for Graphy Inc.’s shape-memory alloy (SMA) clear aligners have increased by more than 50% so far this year. The company’s centralized manufacturing business is showing strong growth, driven by…
2026-11-19 07:59:02